[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 6 of about 6
1. Lange TS, Kim KK, Singh RK, Strongin RM, McCourt CK, Brard L: Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells. PLoS One; 2008 May 28;3(5):e2303
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In this pioneer study to the biological activity of organometallic compound Iron(III)-salophene (Fe-SP) the specific effects of Fe-SP on viability, morphology, proliferation, and cell-cycle progression on platinum-resistant ovarian cancer cell lines were investigated.
  • METHODOLOGY/PRINCIPAL FINDINGS: Fe-SP displayed selective cytotoxicity against SKOV-3 and OVCAR-3 (ovarian epithelial adenocarcinoma) cell lines at concentrations between 100 nM and 1 microM, while the viability of HeLa cells (epithelial cervix adenocarcinoma) or primary lung or skin fibroblasts was not affected.
  • SKOV-3 cells in contrast to fibroblasts after treatment with Fe-SP revealed apparent hallmarks of apoptosis including densely stained nuclear granular bodies within fragmented nuclei, highly condensed chromatin and chromatin fragmentation.
  • Fe-SP exerted effects as an anti-proliferative agent with an IC(50) value of 300 nM and caused delayed progression of cells through S-phase phase of the cell cycle resulting in a complete S-phase arrest.
  • When intra-peritoneally applied to rats Fe-SP did not show any systemic toxicity at concentrations that in preliminary trials were determined to be chemotherapeutic relevant doses in a rat ovarian cancer cell model.
  • CONCLUSION/SIGNIFICANCE: The present report suggests that Fe-SP is a potent growth-suppressing agent in vitro for cell lines derived from ovarian cancer and a potential therapeutic drug to treat such tumors in vivo.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1998 Aug 28;281(5381):1312-6 [9721091.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33533-9 [9837934.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1037-45 [10400419.001]
  • [Cites] Nat Cell Biol. 1999 Jul;1(3):E73-9 [10559915.001]
  • [Cites] J Clin Invest. 1999 Dec;104(12):1645-53 [10606615.001]
  • [Cites] Nucleic Acids Res. 1999 Nov 1;27(21):4160-6 [10518606.001]
  • [Cites] J Med Chem. 2004 Nov 18;47(24):5837-46 [15537341.001]
  • [Cites] Free Radic Biol Med. 2005 Jan 1;38(1):58-69 [15589372.001]
  • [Cites] Biochem Pharmacol. 2005 Apr 1;69(7):1009-39 [15763539.001]
  • [Cites] J Inorg Biochem. 2005 Jul;99(7):1433-40 [15878622.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9756-60 [16785432.001]
  • [Cites] Arch Pharm (Weinheim). 2007 Mar;340(3):117-26 [17315259.001]
  • [Cites] Biochem Pharmacol. 2007 Jun 30;74(1):118-30 [17475222.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Jul 1;17(13):3774-7 [17466518.001]
  • [Cites] Chem Biol Drug Des. 2007 Oct;70(4):302-10 [17937776.001]
  • [Cites] Genes Dev. 2007 Nov 15;21(22):2908-22 [18006686.001]
  • [Cites] J Inorg Biochem. 2008 Apr;102(4):740-7 [18180039.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):240-9 [18329084.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):153-83 [11294822.001]
  • [Cites] J Cell Biol. 2002 Apr 29;157(3):441-53 [11980919.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Jun;42(3):213-5 [12050015.001]
  • [Cites] J Med Chem. 2002 Sep 26;45(20):4549-58 [12238934.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):160-2 [14522248.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):65-75 [14965268.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2774-84 [15077141.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):772-8 [15361183.001]
  • [Cites] Arch Biochem Biophys. 1994 Nov 15;315(1):74-81 [7979408.001]
  • [Cites] Eur J Clin Pharmacol. 1994;47(1):1-16 [7988618.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] Curr Opin Cell Biol. 1995 Jun;7(3):337-43 [7662363.001]
  • [Cites] Bioorg Med Chem. 1996 Aug;4(8):1185-96 [8879539.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1659-64 [8939847.001]
  • [Cites] Bioconjug Chem. 1997 Nov-Dec;8(6):789-92 [9404650.001]
  • [Cites] Bioconjug Chem. 1997 Nov-Dec;8(6):798-812 [9404652.001]
  • [Cites] Toxicology. 1997 Dec 31;124(3):179-92 [9482120.001]
  • [ErratumIn] PLoS ONE. 2008;3(7). doi: 10.1371/annotation/d97d24fc-aa07-40fd-88b2-6b2e050ddb31
  • (PMID = 18509533.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043447; United States / NCRR NIH HHS / RR / P20 RR018728; United States / NCRR NIH HHS / RR / 1-P20RR018728
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ferric Compounds; 0 / Iron(III)-salophene; 49DFR088MY / Platinum
  • [Other-IDs] NLM/ PMC2386551
  •  go-up   go-down


2. Wang L, Chang X, Yuan G, Zhao Y, Wang P: Expression of peptidylarginine deiminase type 4 in ovarian tumors. Int J Biol Sci; 2010;6(5):454-64
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of peptidylarginine deiminase type 4 in ovarian tumors.
  • Peptidylarginine deiminase type 4 (PADI4) converts arginine residues into citrulline.
  • We utilized immunohistochemistry, real-time PCR and western blotting to analyze the expression of PADI4 in the tumor tissues and in the cell line that were cultured with estrodial-17β.
  • PADI4 was detected in serious cystadenocarcinoma (n=39, positivity=100%), clear cell cancer (n=7, positivity= 100%), mucinous cystadenocarcinoma (n=6, positivity=100%), dysgerminoma (n=6, positivity=100%), squamous cell tumor (n=6, positivity=100%), sibnet-ring cell carcinoma (n=6, positivity=100%), endodermal sinus tumor (n=6, positivity=100%), germ cell tumors (n=6, positivity=100%) and immature teratoma (n=6, positivity=100%).
  • However, PADI4 was either not detected or detected at low levels in granulosa cell tumor (n=6), malignant thecoma (n=6), ovarian cystadenoma (n=5) and normal ovarian tissue (n=11).
  • However, PADI4 showed granular cellular distribution in the tumor tissues that were isolated from grade I cystadenocarcinoma.
  • In addition, the PADI4 level was positively related with the ages of the patients that presented with serious adenocarcinoma (p=0.029).
  • Real-time PCR and western blot analyses confirmed that PADI4 was expressed at higher levels in ovarian adenocarcinoma (n=8) compared to ovarian cystadenoma (n=5) (p< 0.05).
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Estradiol / pharmacology. Estradiol / physiology. Female. Gene Expression / drug effects. Humans. Immunohistochemistry. Polymerase Chain Reaction. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 1998 Aug;19(4):397-428 [9715373.001]
  • [Cites] J Biol Chem. 2008 Jul 18;283(29):20060-8 [18499678.001]
  • [Cites] Int Immunol. 1998 Dec;10(12):1891-5 [9885910.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Dec;49(6):695-707 [10209555.001]
  • [Cites] Rheumatology (Oxford). 2005 Jan;44(1):40-50 [15466895.001]
  • [Cites] Endocrine. 2005 Apr;26(3):297-300 [16034185.001]
  • [Cites] BMC Cancer. 2009;9:40 [19183436.001]
  • [Cites] J Leukoc Biol. 2001 Jul;70(1):46-51 [11435484.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 25;290(3):979-83 [11798170.001]
  • [Cites] Oncologist. 2002;7(1):73-81 [11854549.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49562-8 [12393868.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1180-9 [12637488.001]
  • [Cites] Ann Rheum Dis. 2004 Apr;63(4):373-81 [15020330.001]
  • [Cites] Cell. 2004 Sep 3;118(5):545-53 [15339660.001]
  • [Cites] Science. 2004 Oct 8;306(5694):279-83 [15345777.001]
  • [Cites] Acta Radiol Oncol. 1980;19(4):241-4 [6257044.001]
  • [Cites] Cancer Surv. 1994;19-20:287-307 [7895220.001]
  • [Cites] Am J Epidemiol. 1995 May 1;141(9):828-35 [7717359.001]
  • [Cites] Mol Carcinog. 2006 Mar;45(3):183-96 [16355400.001]
  • [Cites] Apoptosis. 2006 Feb;11(2):183-96 [16502257.001]
  • [Cites] Mol Endocrinol. 2007 Jul;21(7):1617-29 [17456793.001]
  • [Cites] Hum Reprod Update. 2007 Sep-Oct;13(5):453-63 [17573406.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):266-73 [17698176.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10746-50 [9724775.001]
  • (PMID = 20827398.001).
  • [ISSN] 1449-2288
  • [Journal-full-title] International journal of biological sciences
  • [ISO-abbreviation] Int. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / RNA, Messenger; 4TI98Z838E / Estradiol; EC 3.- / Hydrolases; EC 3.5.3.15 / peptidylarginine deiminase type IV
  • [Other-IDs] NLM/ PMC2935668
  • [Keywords] NOTNLM ; Peptidylarginine deiminase type 4 (PADI4/PAD4) / estrodial-17β. / ovarian cancer (OCa)
  •  go-up   go-down


3. Honda K, Ishiko O, Wakasa K, Sumi T, Kawamura N, Ogita S: Induction of estradiol synthesis by probucol in the adenocarcinoma cells of an ovarian clear cell tumor. Anticancer Res; 2000 Nov-Dec;20(6B):4397-401
Hazardous Substances Data Bank. ESTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of estradiol synthesis by probucol in the adenocarcinoma cells of an ovarian clear cell tumor.
  • BACKGROUND: Clear cell tumor of Müllerian organs have characteristic intracellular structures with numerous small mitochondria, free ribosomes, lamellae of granular endoplasmic reticulum and intracytoplasmic glycogen granules, but synthesize no estrogens under ordinary conditions.
  • MATERIALS AND METHODS: Cells from an ovarian clear cell tumor cultured with 10 micrograms/ml of the antioxidant probucol released more estradiol into the medium than cells cultured without probucol.
  • Immunocytological analysis revealed the predominance of estradiol in the adenocarcinoma cells cultured with probucol.
  • RESULTS: There was no difference in the distribution of low-density lipoprotein receptors in adenocarcinoma cells according to whether they had been cultured with or without probucol.
  • Cytochemical analysis showed that hydroxylation of estrone was accelerated in the adenocarcinoma cells cultured with probucol as compared to the cells cultured without probucol.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Anticholesteremic Agents / pharmacology. Antioxidants / pharmacology. Estradiol / biosynthesis. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Probucol / pharmacology
  • [MeSH-minor] Estrone / biosynthesis. Female. Humans. Receptors, LDL / analysis. Receptors, LDL / drug effects

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205278.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Antioxidants; 0 / Neoplasm Proteins; 0 / Receptors, LDL; 2DI9HA706A / Estrone; 4TI98Z838E / Estradiol; P3CTH044XJ / Probucol
  •  go-up   go-down


5. Uzdensky A, Juzeniene A, Ma LW, Moan J: Photodynamic inhibition of enzymatic detachment of human cancer cells from a substratum. Biochim Biophys Acta; 2004 Jan 5;1670(1):1-11
Hazardous Substances Data Bank. ROTENONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is shown that sublethal PDT of human WiDr adenocarcinoma cells and D54Mg glioblastoma cells with 5-aminolevulinic acid (ALA), disulfonated tetraphenylporphyrine (TPPS(2a)), or MitoTracker Red (MTR) inhibits their trypsin-induced detachment from a plastic substratum.
  • Both granular and diffuse fluorescence of ALA-derived protoporphyrin IX (PpIX) was observed in the perinuclear cytoplasm but not in the plasma membrane of WiDr cells stained for 2 h with 1 mM ALA.
  • PpIX retained in the plasma membrane during efflux may be responsible for PDT-induced impairment of cell adhesion.
  • On the other hand, MTR-PDT or ALA-PDT after 15-min incubation, when the newly synthesized PpIX should remain in mitochondria, also inhibited enzymatic cell detachment.
  • Therefore, photodynamic targeting of mitochondria, remote from the cell surface where adhesion occurs, may disturb cell adhesion.
  • Photodynamic inhibition of enzymatic cell detachment may be related to PDT-induced inhibition of tumour metastasis.
  • [MeSH-major] Cell Adhesion / drug effects. Cell Membrane / drug effects. Photochemotherapy. Photosensitizing Agents / pharmacology. Protoporphyrins. Trypsin Inhibitors / pharmacology
  • [MeSH-minor] Adenocarcinoma. Aminolevulinic Acid / chemistry. Aminolevulinic Acid / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Fluorescent Dyes / pharmacology. Glioblastoma. Humans. Microscopy, Fluorescence. Organic Chemicals. Porphyrins / pharmacology. Rotenone / pharmacology. Spectrometry, Fluorescence. Trypsin / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14729136.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Organic Chemicals; 0 / Photosensitizing Agents; 0 / Porphyrins; 0 / Protoporphyrins; 0 / Trypsin Inhibitors; 0 / di(4-sulfonatophenyl)diphenylporphine; 0 / red dye CMXRos; 03L9OT429T / Rotenone; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


6. Wang J, Jin Y, Xu Z, Zheng Z, Wan S: Involvement of caspase-3 activity and survivin downregulation in cinobufocini-induced apoptosis in A 549 cells. Exp Biol Med (Maywood); 2009 May;234(5):566-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cinobufocini injection is a preparation containing water-soluble components of the toad skin.
  • The aim of the present study was to investigate the apoptosis of human lung adenocarcinoma cell line A 549 induced by cinobufocini.
  • We found that cinobufocini significantly inhibited tumor growth of A 549 cells in a dose- and time-dependent manner without damaging non-cancerous cells (HLF-1) and induced granular apoptotic bodies of A 549 cells.
  • [MeSH-major] Apoptosis / drug effects. Bufanolides / pharmacology. Caspase 3 / biosynthesis. Down-Regulation / drug effects. Microtubule-Associated Proteins / biosynthesis
  • [MeSH-minor] Caspase 7 / biosynthesis. Cell Line, Tumor. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. G1 Phase / drug effects. Humans. Inhibitor of Apoptosis Proteins. S Phase / drug effects. Up-Regulation / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19244543.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Bufanolides; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / chan su; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP7 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7
  •  go-up   go-down






Advertisement